Patients with and without HIV had similar 1- and 3-year survival outcomes following kidney transplantation, however, 5-year survival outcomes differed significantly.

Investigators analyzed biopsy histology from a subset of patients with lupus nephritis treated with obinutuzumab vs placebo in the phase 3 REGENCY trial ...

Significantly lower odds of overactive bladder reported for individuals in the highest versus lowest quartile of alternative Mediterranean diet score.

(HealthDay News) — A new tool can predict individualized probability of survival with conservative management (CM) versus dialysis transition among individuals with advanced chronic kidney disease ...

(HealthDay News) — Long-term melatonin use for treatment of insomnia is associated with a higher risk for incident heart failure and all-cause mortality, according to a study to be presented at the ...

(HealthDay News) — Patients with gastroesophageal reflux disease (GERD) have increased odds of new alcohol use disorder (AUD) diagnosis, according to a study published online Oct. 20 in the Journal of ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Findings seen for lipoprotein a, remnant cholesterol, and high-sensitivity C-reactive protein.

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

Results of CheckMate 67T, a phase 3 noninferiority study comparing subcutaneous and intravenous nivolumab formulations in RCC, were presented at JADPRO 2025.

A phase 2 RCT evaluated progression of prostate-specific antigen and urinary symptoms in men with low-risk prostate cancer who were administered phytochemical-rich food and Lactobacillus probiotic ...

No significant increase in hazard ratios seen for GI events for semaglutide versus dulaglutide, tirzepatide versus dulaglutide, tirzepatide versus semaglutide.